(Total Views: 752)
Posted On: 08/02/2020 1:24:48 PM
Post# of 148944
Speaking of "full recovery" by day 14 in M/M patients.
Dr. Yang said not all of his patients responded to Leronlimab as well as Mottet and the trial results will offer more insight into its efficacy. But when he last read her antibody count, it was over 100,000.
“She’s about 10 times higher than the typical person’s antibodies,” Dr. Yang said.
Dr. Yang recently published a study on antibodies in COVID-19 patients in the New England Journal of Medicine, and found that antibodies fall sharply in the first three months after battling the virus, especially in mild cases of COVID-19. But Mottet was a rare exception.
“I feel like the safest person anybody can be around right now,” Mottet said.
https://spectrumnews1.com/ca/la-east/coronavi...-recovery#
Yang et al letter to NEJM
https://www.nejm.org/doi/full/10.1056/NEJMc20...tured_home
Dr. Yang said not all of his patients responded to Leronlimab as well as Mottet and the trial results will offer more insight into its efficacy. But when he last read her antibody count, it was over 100,000.
“She’s about 10 times higher than the typical person’s antibodies,” Dr. Yang said.
Dr. Yang recently published a study on antibodies in COVID-19 patients in the New England Journal of Medicine, and found that antibodies fall sharply in the first three months after battling the virus, especially in mild cases of COVID-19. But Mottet was a rare exception.
“I feel like the safest person anybody can be around right now,” Mottet said.
https://spectrumnews1.com/ca/la-east/coronavi...-recovery#
Yang et al letter to NEJM
https://www.nejm.org/doi/full/10.1056/NEJMc20...tured_home
(2)
(0)
Whatever happens, we have got
Le-Ron-Li-Mab, and they have not.
Le-Ron-Li-Mab, and they have not.
Scroll down for more posts ▼
